DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Palantir, Moderna, Ulta Beauty, Alibaba and more
▼ + stars: | 2024-11-15 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

Global pharma stocks — Shares of several vaccine makers declined after President-elect Donald Trump selected prominent vaccine skeptic Robert F. Kennedy Jr. as health secretary on Thursday. Shares of Moderna and Pfizer slipped nearly 9% and 5%, respectively. Ulta slipped nearly 3% after Berkshire Hathaway revealed in a regulatory filing that it had sold around 97% of its shares, nearly dissolving its position in the beauty retailer. Berkshire had just bought the stock in the second quarter, making Ulta a relatively new bet. However, the company beat expectations on both lines in the fourth fiscal quarter and issued positive guidance for adjusted earnings per share.

Persons: Donald Trump, Robert F, Kennedy Jr, Eli Lilly, Warren Buffett, Berkshire Hathaway, Ulta, — CNBC's Sean Conlon, Alex Harring, Jesse Pound, Hakyung Kim, Lisa Han Organizations: Global pharma, Moderna, Pfizer, GSK, Novo Nordisk, Nasdaq, Securities and Exchange Commission, Super, New York Stock Exchange, Corp, Berkshire, Pool Corp, AST, Materials, LSEG Locations: China, Domino's, Berkshire

☆ Tariffs could have trickle-down effects across global pharmaceutical industry, says CEO
▼ + stars: | 2024-11-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTariffs could have trickle-down effects across global pharmaceutical industry, says CEOJohn Graham, Group CEO of Zuellig Pharma, talks about election risks, US-China tensions, and how tariffs and protectionism could affect the pharmaceutical industry.

Persons: John Graham Organizations: Zuellig Pharma Locations: China

☆ Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well
▼ + stars: | 2024-11-01 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDaiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very wellDaiichi Sankyo's chief operating officer, Hiroyuki Okuzawa speaks about the company's drug pipeline and alliances with global pharmaceutical firms.

Persons: Hiroyuki Okuzawa Organizations: Merck, AstraZeneca

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

☆ We're raising our price target on Danaher stock as it sheds a major overhang
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

That improvement in the bioprocessing end market is super important because it has been a huge overhang for Danaher shares, and the life sciences space in general. We were concerned about the bioprocessing market after rival Sartorius cut its guidance last week. The management team has effectively navigated the bioprocessing slowdown better than others and kept expectations managed — a big reason we've stuck by the stock during a difficult few quarters. Based on these strong results and the improving bioprocessing market, we are raising our price target to $295 from $280 and reiterating our 1 rating. All three operating segments are expected to post sales decline rates in the low single digits.

Persons: Sartorius, Rainer Blair, Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: Club, Revenue, LSEG, Management, Diagnostics, Leica, Beckman Coulter Diagnostics, Cepheid, CNBC, Getty Locations: bioprocessing, Danaher, U.S, Europe, China, Bioprocessing

WASHINGTON (AP) — U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology, warning of the risks to U.S. national security and commercial interests. Bills have been introduced in the House and Senate to bar “foreign adversary biotech companies of concern” from doing business with federally funded medical providers. Photos You Should See View All 33 ImagesCritics of the legislation warn that restrictions on Chinese companies would impede advances that could bring a greater good. “It’s not just a supply chain battle or a national security battle or an economic security battle; I would submit it’s a moral and ethical battle,” Gallagher said. He said any restrictive U.S. measures should be tailored to address military concerns and concerns about genomic data security.

Persons: walling, ”, Abigail Coplin, Rachel King, Mike Gallagher, Gallagher, “ It’s, ” Gallagher, “ we’re, Biden, Tom Bollyky, Bollyky, Ray Yip, Yip, “, Anna Puglisi, Puglisi, ” Puglisi, BGI, WuXi AppTec, Dake Kang Organizations: WASHINGTON, — U.S, Biotechnology, Bills, Embassy, Biden, Vassar College, Biotechnology Innovation Organization, National Security Commission, Emerging Biotechnology, U.S . Senate, Chinese Communist Party, Wisconsin Republican, “, Bloomberg, Council, Foreign Relations, U.S . Centers for Disease Control, Georgetown University’s Center for Security, Emerging, The Defense Department, Commerce Department, Associated Press Locations: China, U.S, ”, South China, Wisconsin, Boston, United States, WuXi, Beijing

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

☆ Sanofi CEO under pressure to woo investors after spending shock
▼ + stars: | 2023-12-05 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend. David Song, a portfolio manager and investment partner at Tema ETF, said: "The narrative of Sanofi has been a margin expansion, earnings-driven story for a lot of investors." "Shouldn't investors give credit to managements who care about long-term shareholder value creation?," said Song. ($1 = 0.9206 euros)Reporting by Ludwig Burger; Editing by Josephine Mason and Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Paul Hudson, Sanofi, Benoit Tessier, Hudson, Dan Lyons, Janus Henderson, Markus Manns, David Song, Fabian Wenner, Julius Baer, Union's Manns, Janus Henderson's Lyons, Johnson, Song, Ludwig Burger, Josephine Mason, Emelia Organizations: REUTERS, Reuters, Janus Henderson Investors, Germany's Union Investment, Tema, Thomson Locations: Paris, France, British, Hudson, Denver, Swiss, Tema

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ Sanofi loses $21 billion in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( ) www.cnbc.com time to read: +2 min

Chesnot | Getty ImagesSanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business to focus on its core innovative drugs business. Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability." Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data. Bayer, led by a new CEO since June, has faced calls by several investors to split off its consumer business. EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target.

Persons: Sanofi, drugmaker, Paul Hudson, Terence McManus, Kenvue, Johnson, Bayer Organizations: Chesnot, Getty, Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer Locations: Gentilly, Paris, France, Bellevue

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

☆ GSK raises $1.1 billion from Haleon stake sale
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsOct 6 (Reuters) - British drugmaker GSK (GSK.L) on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon (HLN.L), cutting its shareholding to 7.4% in the world's largest standalone consumer healthcare firm. The sale of 270 million shares at 328 pence apiece, represented a discount of about 2.5% to Haleon's last close of 336.25 pence on Thursday. Shares in Haleon were down 1.2% while GSK was marginally up 0.4% at 0800 GMT. Pfizer, which holds a 32% stake in Haleon, said in May it plans to cut its ownership in a "slow and methodical" manner within months. The British drugmaker and Pfizer have agreed to not sell any further Haleon shares for 60 days from the settlement of placing.

Persons: Dado Ruvic, Emma Walmsley, Prerna Bedi, Sonia Cheema, Elaine Hardcastle Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, London Stock Exchange, Pfizer, Thomson Locations: Haleon, British, Bengaluru

“With us, you know what you get, which is rare nowadays!” Alexandre Edelmann, head of Presence Switzerland, a government agency that promotes the country abroad, says in an email. “People love our country without always knowing why,” says Jacques Pitteloud, Switzerland’s ambassador to the U.S. and a veteran diplomat. We are constantly leading the pack in terms of innovation.”This is evident in the prominent role Switzerland plays in some key areas of the global economy. Acknowledging "the elephant in the room," Pitteloud says Switzerland and the EU have "a complex relationship." And as a relatively small, landlocked country in which many areas are difficult to inhabit due to terrain, Switzerland is facing challenges related to population and resources.

Persons: Roger Federer, Philippe, –, Alexandre Edelmann, ”, Jacques Pitteloud, Pitteloud, ” Delphine Donné, Ruag, yearslong, ” Georg Klingler, Donné Organizations: Wimbledon, U.S . News, European Union, Bank, Presence Switzerland, Nestle, Roche, Novartis, Atlas, Logitech, ETH Zurich, Zurich University of Applied Sciences, EU, Greenpeace, Associated Press Locations: Switzerland, Europe, U.S, Swiss, France, China, Canada, Lausanne, Ukraine, Greenpeace Switzerland

☆ This biotech stock is a cancer-fighting 'powerhouse' with nearly 50% upside, says Jefferies
▼ + stars: | 2023-08-17 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Investors should keep an eye on biotech company BeiGene as it scales up its global revenue streams, according to Jefferies. Analyst Kelly Shi initiated coverage of the stock with a buy rating and assigned a price target of $287, suggesting shares stand to gain 49.2% in the next 12 months. The stock has lost 12% so far this year but has had a more uplifting quarter with gains of about 8%. According to the analyst, BeiGene's product pipeline could expand beyond oncology, as it currently includes early autoimmune candidates. BeiGene's tislelizumab drug is another major growth driver for the company, Shi said, highlighting the drug's position as China's top-selling PD-1 drug with about 40% market share.

Persons: Kelly Shi, Shi, BeiGene, BGNE, Amgen, — CNBC's Michael Bloom Organizations: Jefferies, pharma, Novartis Locations: Cambridge , Massachusetts, Beijing, China, BeiGene

☆ Top 10 things to watch in the stock market Friday, including hotter PPI and mega-cap pressure
▼ + stars: | 2023-08-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Top 10 things to watch Friday, Aug. 11 Stocks are lower to end the week. Apple (AAPL) and Nvidia (NVDA), the Club's two "own it, don't trade it" stocks and big 2023 winners, are under pressure again early Friday. Target (TGT) price target lowered to $142 per share from $163 by Barclays; and $160 from $200 by Guggenheim ahead of earnings next Wednesday. Credit Suisse raises its earnings estimates and price target on Walmart (WMT) to $180 from $170 ahead of its report next week. Club name Pioneer Natural Resources (PXD) price target raised to $281 per share from $275 at Stifel.

Persons: Dow, Stanley Black, Decker, Stanley, Eli Lilly, Piper Sandler, Piper, Guggenheim, Jim Cramer's, Jim Cramer, Jim Organizations: Caterpillar, Apple, Nvidia, Wolf Research, Citi, Merck, Cisco Systems, Arista Networks, Juniper Networks, Palo Alto Networks, Barclays, Credit Suisse, Walmart, Natural Resources, Energy, Halliburton, HAL, JPMorgan, Netflix, Jim Cramer's Charitable, CNBC Locations: Stifel

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market. Foreign pharmaceuticals firms have struggled to cement any inroads they have made into the world's second-largest economy, with the government maintaining a drug procurement programme that forces them to slash their prices and refusing to approve the use of any foreign COVID-19 vaccines during the pandemic. But as China pursues home-grown modernisation it will also open up "more development opportunities for foreign-funded enterprises, including the pharmaceutical industry," Wang told the meeting. Wang told the meeting on Wednesday that his ministry will expand the channels of communication for responding to and solving concerns, with the meeting resulting in 25 specific suggestions to be taken forward. Reporting by Joe Cash; Additional reporting by Kevin Yao;Editing by Elaine HardcastleOur Standards: The Thomson Reuters Trust Principles.

Persons: Roche, Takeda, Wang Wentao, Wang, Li Qiang, Li, drugmakers, Joe Cash, Kevin Yao, Elaine Hardcastle Organizations: China's Commerce, AstraZeneca, Bayer, Merck, Novo Nordisk, Pfizer, Sanofi, Moderna, Wednesday, Economic, Thomson Locations: BEIJING, China, Tianjin

The World Health Organization is working with countries to investigate the global pharmaceutical supply chain for such syrups. Andika Urrasyidin, lead police investigator of the case, told Reuters police have called in "many" BPOM officials for questioning, and the investigation is still underway. Hersadwi Rusdiyono, the director of Indonesia's national police's crimes detection unit, said BPOM officials were brought in as witnesses, but investigators are now checking if any wrongdoing was committed by drug regulators. "We asked them according to their functions, as regulators, whether they've conducted supervision and what kind of supervision," he told Reuters. Hersadwi said the probe so far has focused on staff at lower levels and not included BPOM'S chief, Penny Lukito.

Persons: Urrasyidin, Hersadwi Rusdiyono, they've, Hersadwi, Penny Lukito, Penny, BPOM, Tirta Buana Kemindo, Stanley Widianto, Miyoung Kim, Sara Ledwith, Michele Gershberg Organizations: Reuters, World Health Organization, Police, Afi, Thomson Locations: JAKARTA, Gambia, Uzbekistan, BPOM

A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection. "The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," he said. He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect. Bayer shares lag'HIGHLY ATTRACTIVE'In the United States, a different set of drug market rule changes are underway, with some of the highest-selling products set to see negotiated price discounts under the Inflation Reduction Act (IRA). Among the biggest drivers was the company's decision to prepare a U.S. launch of its next-generation stroke prevention drug asundexian on its own.

☆ Over-the-counter eye drop has been linked to infections leading to eyeball removal, vision loss, and one death: CDC
▼ + stars: | 2023-03-19 | by ( Aidan Pollard | ) www.businessinsider.com time to read: +2 min

EzriCare eye drops were recalled in February over possible bacterial contamination. The CDC recommends avoiding EzriCare and Delsam Pharma Artificial Tears. EzriCare Artificial Tears, an over-the-counter eye drop made by Global Pharma Healthcare, was recalled in early February, NBC News reported. According to the CDC, most patients reported using eye drops — and many reported using EzriCare specifically. EzriCare and Delsam Pharma drops were distributed across the US over the internet, according to Global Pharma Healthcare.

☆ U.S. FDA says India-made eye drop linked to some infections, blindness and one death
▼ + stars: | 2023-02-03 | by ( ) www.reuters.com time to read: +2 min

The agency said on Thursday that Artificial Tears eye drop manufactured by India's Global Pharma Healthcare Pvt Ltd has a potential bacterial contamination and the company has violated current good manufacturing practices. Global Pharma Healthcare did not immediately respond to a Reuters request seeking comment on the FDA statement. EzriCare said in a statement on Wednesday that it had stopped further distribution and sale of the eye drop, and it was not aware of any testing that "definitively links" the bacterial outbreak to the product. It said that as of Jan. 31, the CDC had identified 55 patients in 12 states with infections linked to the use of Artificial Tears distributed by EzriCare, it said. "Associated adverse events include hospitalization, one death with bloodstream infection, and permanent vision loss from eye infections," the FDA said.

☆ Exclusive: WHO investigating links between cough syrup deaths, considers advice for parents
▼ + stars: | 2023-01-24 | by ( Jennifer Rigby | ) www.reuters.com time to read: +6 min

The deaths of children from acute kidney injury began in July 2022 in Gambia, followed by cases in Indonesia and Uzbekistan. The WHO has said the deaths are linked to over-the-counter cough syrups the children took for common illnesses and which contained a known toxin, either diethylene glycol or ethylene glycol. The WHO, working with Indonesia’s drugs regulator, also issued an alert in October about cough syrups made by four Indonesian manufacturers and sold domestically. The manufacturers are: PT Yarindo Farmatama, PT Universal Pharmaceutical, PT Konimex, PT AFI Farma. PT Universal Pharmaceutical Industries’ lawyer, Hermansyah Hutagalung, said it had pulled from the market all cough syrups deemed dangerous.

☆ I prescribe the popular weight-loss drug semaglutide to my patients. I hesitate to call it a magic bullet.
▼ + stars: | 2023-01-18 | by ( Hannah Moseley | ) www.businessinsider.com time to read: +7 min

Dr. Paul Kolodzik has been prescribing semaglutide to his diabetic patients since 2017. The one regret he hears from patients on the drug is they can't enjoy food as much. Before that, I was an emergency physician for about 25 years, caring for patients with strokes, heart attacks, and diabetic emergencies. I started prescribing semaglutide under the label Ozempic to my diabetic patients in 2017Novo Nordisk, a global pharmaceutical company, developed Ozempic as a medication for diabetics to control their blood sugar. So, physicians started prescribing some patients who weren't diabetic Ozempic off-label since Ozempic is not approved for weight loss — even though it's the same generic medicine.

☆ Big Pharma will find right formula for M&A binge
▼ + stars: | 2022-12-20 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

The year 2022 was relatively thin for pharma M&A, with deals worth nearly $66 billion being announced by early December – 60% below the 9-year average, according to Refinitiv data; 2023 will be better. It helps that drug companies are relatively healthy, with debt around just 1.6 times forecast EBITDA in 2023, according to Berenberg analysts. Seagen (SGEN.O), for example, worth $22 billion in early December, has fought off Merck & Co (MRK.N). That puts Big Pharma in an ideal negotiating position. CONTEXT NEWSGlobal pharmaceutical companies spent nearly $66 billion on takeovers in 2022, according to data from Refinitiv as of Dec. 7.

☆ Much of biopharma industry yet to set any climate impact targets - report
▼ + stars: | 2022-11-09 | by ( Natalie Grover | ) www.reuters.com time to read: +4 min

The report, authored by My Green Lab in collaboration with with Urgentem, an independent provider of emissions data, examined direct and indirect carbon emissions created by hundreds of companies in the biopharma industry from publicly available and inferred data. Reporting of scope 3 emissions remains imperfect, there is no standardisation on how this data is gathered and measured, said Connelly. "So some companies do have significantly higher carbon emissions for scope 3, while others are significantly lower, or it may just be that they are reporting quite differently from their peers." Executives from companies big and small told Reuters they were optimistic about strides being made towards cutting carbon output in the industry. The report was supported by the United Nation's High Level Climate Champions team.

☆ GSK picks Burberry's Brown as CFO
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/SummarySummary Companies Brown to join GSK in April, start as CFO in MayCFO Iain Mackay to retireSept 26 (Reuters) - GSK (GSK.L) named luxury fashion brand Burberry's (BRBY.L) Julie Brown as its new chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business. The change comes after GSK spun off its large consumer business, Haleon (HLN.L), to focus on prescription drugs and vaccines. Burberry had said on Friday that Brown would step down as its CFO and chief operating officer in April to take up a role outside the luxury industry. Register now for FREE unlimited access to Reuters.com RegisterReporting by Amna Karimi and Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu and Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Global pharma"

25 mentions found